{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:51:56Z","timestamp":1792065116815,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":193,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NAM Journal"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.namjnl.2026.100114","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:13:28Z","timestamp":1783984408000},"page":"100114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of the FDA roadmap and perspectives for regulatory use of new approach methodologies in Japanese pharmaceutical companies"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-2156","authenticated-orcid":false,"given":"Tetsuro","family":"Araki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Naraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3783-0721","authenticated-orcid":false,"given":"Yuta","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9868","authenticated-orcid":false,"given":"Toru","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kurashige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Shinozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimika","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.namjnl.2026.100114_bib0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12910-019-0352-3","article-title":"Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations","volume":"20","author":"Bailey","year":"2019","journal-title":"BMC Med. Ethics"},{"key":"10.1016\/j.namjnl.2026.100114_bib0002","first-page":"297","article-title":"Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate)","volume":"39","author":"Baran","year":"2022","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2026.100114_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41573-025-01182-9","article-title":"Application of new approach methodologies for nonclinical safety assessment of drug candidates","volume":"24","author":"Beilmann","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.namjnl.2026.100114_bib0004","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.yrtph.2018.04.018","article-title":"A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans","volume":"96","author":"Clark","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.namjnl.2026.100114_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.106007","article-title":"A CDER perspective: Landscape of New Approach Methodologies (NAMs) submitted in drug development programs","volume":"165","author":"Dao","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.namjnl.2026.100114_bib0006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/d41573-025-00052-8","article-title":"Insights into new approach methodology innovation: an EMA perspective","volume":"24","author":"Edwards","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.namjnl.2026.100114_bib0007","unstructured":"EMA, 2009. Qualification of novel methodologies for drug development: guidance to applicants. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-novel-methodologies-drug-development-guidance-applicants_en.pdf (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0008","unstructured":"FDA, 2020. Qualification process for drug development tools, guidance for industry and FDA staff. https:\/\/www.fda.gov\/media\/133511\/download (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0009","unstructured":"FDA, 2022. Nonclinical considerations for mitigating nonhuman primate supply constraints arising from the COVID-19 pandemic, guidance for industry. https:\/\/digirepo.nlm.nih.gov\/master\/borndig\/9918451285806676\/9918451285806676.pdf (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0010","unstructured":"FDA, 2025. Roadmap to reducing animal testing in preclinical safety studies. https:\/\/www.fda.gov\/files\/newsroom\/published\/roadmap_to_reducing_animal_testing_in_preclinical_safety_studies.pdf (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0011","unstructured":"ICH, 2009. Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. https:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf (accessed 10 June 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0012","unstructured":"ICH, 2012. Questions & answers (R2): guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. https:\/\/database.ich.org\/sites\/default\/files\/M3_R2_Q%26As_R2_Q%26As_0.pdf (accessed 10 June 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0013","unstructured":"IQVIA, 2025. Pharmaceutical trends -top 10 pharmaceutical markets worldwide, 2024. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/canada\/2024-trends\/english\/top10worldwidesales_24.pdf (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0014","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.namjnl.2026.100114_bib0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","article-title":"Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database","volume":"334","author":"Monticello","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.namjnl.2026.100114_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2024.101034","article-title":"Opportunities for microphysiological systems from the view of Japanese industries","volume":"60","author":"Naraoka","year":"2025","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.namjnl.2026.100114_bib0017","doi-asserted-by":"crossref","unstructured":"Nimmerjahn, F., Ravetch, J.V., 2008. Fc\u03b3 receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34\u201347. https:\/\/doi.org\/10.1038\/nri2206.","DOI":"10.1038\/nri2206"},{"key":"10.1016\/j.namjnl.2026.100114_bib0018","doi-asserted-by":"crossref","unstructured":"OECD, 2025. Test no. 437: bovine corneal opacity and permeability test method for identifying I) chemicals inducing serious eye damage and II) chemicals not requiring classification for eye irritation or serious eye damage, OECD guidelines for the testing of chemicals, section 4, OECD Publishing, Paris. https:\/\/doi.org\/10.1787\/9789264203846-en.","DOI":"10.1787\/9789264203846-en"},{"key":"10.1016\/j.namjnl.2026.100114_bib0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.namjnl.2026.100114_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.namjnl.2026.100114_bib0021","unstructured":"PMDA, 2025a. New approach methodologies: NAMs. https:\/\/www.pmda.go.jp\/english\/review-services\/0022.html (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0022","unstructured":"PMDA, 2025b. Thoughts on the use of weight of evidence approach in nonclinical safety evaluation (early consideration). https:\/\/www.pmda.go.jp\/files\/000278903.pdf (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0023","unstructured":"PMDA, 2025c. Use of the weight of evidence approach as an alternative to nonhuman primate developmental and reproductive toxicity testing for biopharmaceuticals (Early consideration). https:\/\/www.pmda.go.jp\/files\/000278904.pdf (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0024","unstructured":"PMDA, 2026. Considerations for the general toxicity evaluation of monoclonal antibodies (early consideration). https:\/\/www.pmda.go.jp\/files\/000280938.pdf (accessed 6 July 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0025","first-page":"98","article-title":"Review on organ-on-chips for medicines safety assessment: a European regulatory perspective","volume":"43","author":"Portela","year":"2026","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2026.100114_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2025.109035","article-title":"New approach methodologies for assessing developmental toxicity of pharmaceuticals: case examples and future directions","volume":"137","author":"Powles-Glover","year":"2025","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.namjnl.2026.100114_bib0027","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/toxres\/tfaa081","article-title":"Justification for species selection for pharmaceutical toxicity studies","volume":"9","author":"Prior","year":"2020","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.namjnl.2026.100114_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104328","article-title":"Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment","volume":"30","author":"Shenton","year":"2025","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.namjnl.2026.100114_bib0029","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.namjnl.2026.100114_bib0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2131\/jts.38.581","article-title":"Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan","volume":"38","author":"Tamaki","year":"2013","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.namjnl.2026.100114_bib0031","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s43441-024-00630-9","article-title":"International comparison of qualification process for medical product development tools","volume":"58","author":"Uchijima","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.namjnl.2026.100114_bib0032","unstructured":"UK Government, 2025. Replacing animals in science. https:\/\/www.gov.uk\/government\/publications\/replacing-animals-in-science-strategy (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0033","unstructured":"US Congress, 2022. S.5002 - FDA modernization Act 2.0. https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/5002 (accessed 26 March 2026)."},{"key":"10.1016\/j.namjnl.2026.100114_bib0034","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/10915818251384270","article-title":"FDA\/CDER\/OND experience with new approach methodologies (NAMs)","volume":"45","author":"Yao","year":"2026","journal-title":"Int. J. Toxicol."}],"container-title":["NAM Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050620426000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050620426000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:05:21Z","timestamp":1792062321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050620426000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"alternative-id":["S3050620426000394"],"URL":"https:\/\/doi.org\/10.1016\/j.namjnl.2026.100114","relation":{},"ISSN":["3050-6204"],"issn-type":[{"value":"3050-6204","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the FDA roadmap and perspectives for regulatory use of new approach methodologies in Japanese pharmaceutical companies","name":"articletitle","label":"Article Title"},{"value":"NAM Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.namjnl.2026.100114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100114"}}